

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4884669

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ORION PHARMA (UK) LIMITED	03/21/2018
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	GENEFORM TECHNOLOGIES LIMITED	
<b>Street Address:</b>	C/O ORION PHARMA (UK) LIMITED	
<b>Internal Address:</b>	5 FLEET PLACE	
<b>City:</b>	LONDON	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	EC4M 7RD	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Patent Number:	8399196
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(215)563-4044	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	215-563-4100	
<b>Email:</b>	docketclerk@ddhs.com	
<b>Correspondent Name:</b>	DANN, DORFMAN, HERRELL AND SKILLMAN	
<b>Address Line 1:</b>	1601 MARKET STREET	
<b>Address Line 2:</b>	SUITE 2400	
<b>Address Line 4:</b>	PHILADELPHIA, PENNSYLVANIA 19103-2307	
<b>ATTORNEY DOCKET NUMBER:</b>	0380-P03782US00	
<b>NAME OF SUBMITTER:</b>	KATHLEEN D. RIGAUT, PH.D.	
<b>SIGNATURE:</b>	/Kathleen D. Rigaut/	
<b>DATE SIGNED:</b>	03/27/2018	
<b>Total Attachments: 2</b>		
source=3782US00_Assignment#page1.tif		
source=3782US00_Assignment#page2.tif		

## ASSIGNMENT OF US PATENT

WHEREAS,

### **ORION PHARMA (UK) LIMITED**

a corporation organized under the laws of England and Wales having a place of business at 5 Fleet Place, London, EC4M 7RD, United Kingdom (hereinafter referred to as the Assignor) is the sole and exclusive owner of the United States Letters Patent set out on Schedule A attached hereto.

AND WHEREAS,

### **GENEFORM TECHNOLOGIES LIMITED**

a corporation organized under the laws of England and Wales, and having a place of business at c/o Orion Pharma (UK) Limited, 5 Fleet Place, London, EC4M 7RD, United Kingdom (hereinafter referred to as the Assignee) is desirous of acquiring the entire right, title and interest in, to and under said Letters Patent so far as the United States of America is concerned;

NOW THEREFORE, in consideration of Ten Dollars (\$10.00) and other good and valuable consideration paid to said Assignor by said Assignee, receipt whereof is hereby acknowledged, the Assignor does hereby assign, sell, transfer and set over unto said Assignee the entire right, title and interest in, to and under said Letters Patent, and any reissue or reissues of said Letters Patent already granted and which may be granted on said Letters Patent, the same to be held and enjoyed by the said Assignee, for its own use and behoof and for the use and behoof of its successors, assigns or other legal representatives, to the end of the term or terms for which Letters Patent of the United States are or may be granted or reissued as fully and entirely as the same would have been held and enjoyed by the said Assignor, if this assignment and sale had not been made; together with all claims for damage by reason of past infringement of said Letters Patent, with the right to sue for, and collect the same for its own use and behoof, and for the use and behoof of its successors, assigns or other legal representatives.

AND, the said Assignor hereby covenants that the Assignor has the full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

### **ORION PHARMA (UK) LIMITED**

Signature: 

Name: Jari Karlson

  
Olli Huotari

Capacity: Board Member

Board Member

Date: 21 March 2018

Place: Espoo

**PATENT**

**REEL: 045357 FRAME: 0653**

SCHEDULE A

<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>
8399196	20 February 2004	NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS